Add Presentation to Slide Tray Presentation:
First- and Second-Generation Antipsychotics for Children and Young Adults
Authors: John H. Coverdale, MD, MEd
What To Discuss With Your Patients and Their Caregivers
- The role that antipsychotics may play as one component in the broader array of treatments for child and adolescent psychiatric disorders.
- The ability of both first-generation and second-generation antipsychotics to improve symptoms of psychiatric disorders in children, and the differences in strength of evidence for benefits in particular indications.
- The risks of neuromotor effects, weight gain, and blood lipid abnormalities, and the evidence about differences in risk among drugs in both classes.
- The limited evidence about long-term benefits and adverse effects on health and quality of life.
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.